Skip to content

Operating Income at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$193.4M+719%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
-$4.62M-124%
AbbVie logo
AbbVieABBV
$3.99B+6.9%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
-$40.82M+1.9%
Alto Neuroscience logo
Alto NeuroscienceANRO
-$27.14M-73.1%
Johnson & Johnson logo
Johnson & JohnsonJNJ

Other financials

Income statement

See full
Net income-$60.7M-172%
EPS (diluted)-$1.34+95.4%

Balance sheet

See full
Cash & equivalents$55.7M
Total debt$5.6M
Total equity$399.8M+285%
Total assets$418.8M

Cash flow

See full
Operating cash flow-$51.2M-100%
CapEx$24.0K
Free cash flow-$51.2M

Valuation

See full
Market cap$1.39B
Enterprise value$1.34B

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio22.9×

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's operating income?
MapLight Therapeutics, Inc. (MPLT) reported operating income of -$64.5M in Q1 2026.
How has MapLight Therapeutics, Inc. 's operating income changed year-over-year?
MapLight Therapeutics, Inc. 's operating income decreased by 174.0% year-over-year, from -$23.54M to -$64.5M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.